Department of Ophthalmology, Dongyang People's Hospital, Dongyang, China.
Clin Exp Optom. 2022 Jul;105(5):520-526. doi: 10.1080/08164622.2021.1943318. Epub 2021 Jul 6.
All eye health care practitioners should know how to control myopia.
Investigating the adjunctive effects of orthokeratology and 0.01% atropine eye drops on controlling the progression of myopia in Chinese children.
The prospective study included Chinese children aged 8 to 13 years having a spherical equivalent refractive error ranging from -2.00 to -5.00 D. Participants were categorised into two groups: combination group (orthokeratology and 0.01% atropine) or atropine group (0.01% atropine). The axial length and spherical equivalent refraction were measured at baseline and every three months post-treatment and compared over two years.
The combinaion and atropine groups comprised 20 and 22 participants. Following two years of treatment, the average spherical equivalent refraction change was 0.88 ± 0.31 D and 1.14 ± 0.63 D in the combination group and atropine group, respectively (P = 0.026), with an average increment in axial length of 0.50 ± 0.17 mm and 0.61 ± 0.21 mm, respectively (P = 0.091). In the atropine group, increased axial length was positively correlated with baseline spherical equivalent refraction (P = 0.018) and negatively correlated with baseline age (P = 0.003). However, these correlations were not observed in the combination group. In the subgroup of subjects aged 8-10 years and another subgroup of subjects with shorter initial axial length (22.00 to 24.50 mm), the changes in axial length over two years were significantly smaller in the combination group than the atropine group.
Orthokeratology and 0.01% atropine eye drops combination therapy were found to be more effective in reducing progression of myopia, as measured through spherical equivalent refraction changes, than atropine monotherapy in children over two years. Combinatorial therapy was more effective in controlling the elongation of axial length in children with younger baseline age or shorter baseline axial length.
所有眼保健医生都应掌握近视控制方法。
研究角膜塑形术联合 0.01%阿托品滴眼液对中国儿童近视进展的辅助作用。
前瞻性研究纳入 8 至 13 岁、球镜等效屈光度为-2.00 至-5.00D 的中国儿童。参与者分为两组：联合组（角膜塑形术联合 0.01%阿托品）或阿托品组（0.01%阿托品）。在基线和治疗后每 3 个月测量眼轴长度和球镜等效屈光度，并在两年内进行比较。
联合组和阿托品组各有 20 名和 22 名参与者。治疗两年后，联合组和阿托品组的平均球镜等效屈光度变化分别为 0.88 ± 0.31D 和 1.14 ± 0.63D（P = 0.026），眼轴长度平均增加 0.50 ± 0.17mm 和 0.61 ± 0.21mm（P = 0.091）。在阿托品组中，眼轴长度的增加与基线球镜等效屈光度呈正相关（P = 0.018），与基线年龄呈负相关（P = 0.003）。然而，在联合组中未观察到这些相关性。在 8-10 岁年龄亚组和初始眼轴长度较短（22.00 至 24.50mm）的亚组中，联合组两年内眼轴长度的变化明显小于阿托品组。
与阿托品单药治疗相比，角膜塑形术联合 0.01%阿托品滴眼液治疗两年后，在降低近视屈光度进展方面更为有效。对于基线年龄较小或基线眼轴较短的儿童，联合疗法在控制眼轴延长方面更为有效。
